|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ohtsu A, Ajani JA, Bai YX, Bang YJ, Chung
HC, Pan HM, Sahmoud T, Shen L, Yeh KH, Chin K, et al: Everolimus
for previously treated advanced gastric cancer: results of the
randomized, double-blind, phase III GRANITE-1 study. J Clin Oncol.
31:3935–3943. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kong J and Lasko P: Translational control
in cellular and developmental processes. Nat Rev Genet. 13:383–394.
2012. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Spilka R, Ernst C, Mehta AK and Haybaeck
J: Eukaryotic translation initiation factors in cancer development
and progression. Cancer Lett. 340:9–21. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Pettersson F, Del Rincon SV and Miller WH
Jr: Eukaryotic translation initiation factor 4E as a novel
therapeutic target in hematological malignancies and beyond. Expert
Opin Ther Targets. 18:1035–1048. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Pelletier J, Graff J, Ruggero D and
Sonenberg N: Targeting the eIF4F translation initiation complex: a
critical nexus for cancer development. Cancer Res. 75:250–263.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chiarini F, Evangelisti C, McCubrey JA and
Martelli AM: Current treatment strategies for inhibiting mTOR in
cancer. Trends Pharmacol Sci. 36:124–135. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Liang S, Guo R, Zhang Z, Liu D, Xu H, Xu
Z, Wang X and Yang L: Upregulation of the eIF4E signaling pathway
contributes to the progression of gastric cancer, and targeting
eIF4E by perifosine inhibits cell growth. Oncol Rep. 29:2422–2430.
2013.PubMed/NCBI
|
|
9
|
Yang W, Raufi A and Klempner SJ: Targeted
therapy for gastric cancer: molecular pathways and ongoing
investigations. Biochim Biophys Acta. 1846:232–237. 2014.PubMed/NCBI
|
|
10
|
Yang HY, Xue LY, Xing LX, Wang J, Wang JL,
Yan X and Zhang XH: Putative role of the mTOR/4E-BP1 signaling
pathway in the carcinogenesis and progression of gastric cardiac
adenocarcinoma. Mol Med Rep. 7:537–542. 2013.PubMed/NCBI
|
|
11
|
Tapia O, Riquelme I, Leal P, Sandoval A,
Aedo S, Weber H, Letelier P, Bellolio E, Villaseca M, Garcia P, et
al: The PI3K/AKT/mTOR pathway is activated in gastric cancer with
potential prognostic and predictive significance. Virchows Arch.
465:25–33. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sun DF, Zhang YJ, Tian XQ, Chen YX and
Fang JY: Inhibition of mTOR signalling potentiates the effects of
trichostatin A in human gastric cancer cell lines by promoting
histone acetylation. Cell Biol Int. 38:50–63. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Abramovich C, Shen WF, Pineault N, Imren
S, Montpetit B, Largman C and Humphries RK: Functional cloning and
characterization of a novel nonhomeodomain protein that inhibits
the binding of PBX1-HOX complexes to DNA. J Biol Chem.
275:26172–26177. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Manavathi B, Lo D, Bugide S, Dey O, Imren
S, Weiss MJ and Humphries RK: Functional regulation of pre-B-cell
leukemia homeobox interacting protein 1 (PBXIP1/HPIP) in erythroid
differentiation. J Biol Chem. 287:5600–5614. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Feng Y, Xu X, Zhang Y, Ding J, Wang Y,
Zhang X, Wu Z, Kang L, Liang Y, Zhou L, et al: HPIP is upregulated
in colorectal cancer and regulates colorectal cancer cell
proliferation, apoptosis and invasion. Sci Rep. 5:94292015.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
van Vuurden DG, Aronica E, Hulleman E,
Wedekind LE, Biesmans D, Malekzadeh A, Bugiani M, Geerts D, Noske
DP, Vandertop WP, et al: Pre-B-cell leukemia homeobox interacting
protein 1 is overexpressed in astrocytoma and promotes tumor cell
growth and migration. Neuro-oncol. 16:946–959. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang SC, Chai DS, Chen CB, Wang ZY and
Wang L: HPIP promotes thyroid cancer cell growth, migration and EMT
through activating PI3K/AKT signaling pathway. Biomed Pharmacother.
75:33–39. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang X, Yang Z, Zhang H, Ding L, Li X, Zhu
C, Zheng Y and Ye Q: The estrogen receptor-interacting protein HPIP
increases estrogen-responsive gene expression through activation of
MAPK and AKT. Biochim Biophys Acta. 1783:1220–1228. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Pan J, Qin Y and Zhang M: HPIP promotes
non-small cell lung cancer cell proliferation, migration and
invasion through regulation of the Sonic hedgehog signaling
pathway. Biomed Pharmacother. 77:176–181. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Xu X, Fan Z, Kang L, Han J, Jiang C, Zheng
X, Zhu Z, Jiao H, Lin J, Jiang K, et al: Hepatitis B virus X
protein represses miRNA-148a to enhance tumorigenesis. J Clin
Invest. 123:630–645. 2013.PubMed/NCBI
|
|
21
|
Feng Y, Li L, Zhang X, Zhang Y, Liang Y,
Lv J, Fan Z, Guo J, Hong T, Ji B, et al: Hematopoietic pre-B cell
leukemia transcription factor interacting protein is overexpressed
in gastric cancer and promotes gastric cancer cell proliferation,
migration, and invasion. Cancer Sci. 106:1313–1322. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Cai W, Ye Q and She QB: Loss of 4E-BP1
function induces EMT and promotes cancer cell migration and
invasion via cap-dependent translational activation of snail.
Oncotarget. 5:6015–6027. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Graff JR, Konicek BW, Vincent TM, Lynch
RL, Monteith D, Weir SN, Schwier P, Capen A, Goode RL, Dowless MS,
et al: Therapeutic suppression of translation initiation factor
eIF4E expression reduces tumor growth without toxicity. J Clin
Invest. 117:2638–2648. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
24
|
Cencic R, Carrier M, Galicia-Vázquez G,
Bordeleau ME, Sukarieh R, Bourdeau A, Brem B, Teodoro JG, Greger H,
Tremblay ML, et al: Antitumor activity and mechanism of action of
the cyclopenta[b]benzofuran, silvestrol. PLoS One. 4:e52232009.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Blagden SP and Willis AE: The biological
and therapeutic relevance of mRNA translation in cancer. Nat Rev
Clin Oncol. 8:280–291. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wang H, Huang F, Wang J, Wang P, Lv W,
Hong L, Li S and Zhou J: The synergistic inhibition of breast
cancer proliferation by combined treatment with 4EGI-1 and MK2206.
Cell Cycle. 14:232–242. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Choo AY, Yoon SO, Kim SG, Roux PP and
Blenis J: Rapamycin differentially inhibits S6Ks and 4E-BP1 to
mediate cell-type-specific repression of mRNA translation. Proc
Natl Acad Sci USA. 105:17414–17419. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Choo AY and Blenis J: Not all substrates
are treated equally: implications for mTOR, rapamycin-resistance
and cancer therapy. Cell Cycle. 8:567–572. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Bhagwat SV, Gokhale PC, Crew AP, Cooke A,
Yao Y, Mantis C, Kahler J, Workman J, Bittner M, Dudkin L, et al:
Preclinical characterization of OSI-027, a potent and selective
inhibitor of mTORC1 and mTORC2: distinct from rapamycin. Mol Cancer
Ther. 10:1394–1406. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Feldman ME, Apsel B, Uotila A, Loewith R,
Knight ZA, Ruggero D and Shokat KM: Active-site inhibitors of mTOR
target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol.
7:e382009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Chresta CM, Davies BR, Hickson I, Harding
T, Cosulich S, Critchlow SE, Vincent JP, Ellston R, Jones D, Sini
P, et al: AZD8055 is a potent, selective, and orally bioavailable
ATP-competitive mammalian target of rapamycin kinase inhibitor with
in vitro and in vivo antitumor activity. Cancer Res. 70:288–298.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Thoreen CC, Kang SA, Chang JW, Liu Q,
Zhang J, Gao Y, Reichling LJ, Sim T, Sabatini DM and Gray NS: An
ATP-competitive mammalian target of rapamycin inhibitor reveals
rapamycin-resistant functions of mTORC1. J Biol Chem.
284:8023–8032. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Benjamin D, Colombi M, Moroni C and Hall
MN: Rapamycin passes the torch: a new generation of mTOR
inhibitors. Nat Rev Drug Discov. 10:868–880. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Naing A, Aghajanian C, Raymond E, Olmos D,
Schwartz G, Oelmann E, Grinsted L, Burke W, Taylor R, Kaye S, et
al: Safety, tolerability, pharmacokinetics and pharmacodynamics of
AZD8055 in advanced solid tumours and lymphoma. Br J Cancer.
107:1093–1099. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Asahina H, Nokihara H, Yamamoto N, Yamada
Y, Tamura Y, Honda K, Seki Y, Tanabe Y, Shimada H, Shi X, et al:
Safety and tolerability of AZD8055 in Japanese patients with
advanced solid tumors; a dose-finding phase I study. Invest New
Drugs. 31:677–684. 2013. View Article : Google Scholar : PubMed/NCBI
|
